Molecular cancer therapy: Tumor suppressor p53 suppresses the expression of SRSF1 via up regulatin of its target gene, 11/May/2014, 8.09 am

Targeting metastatic non-small cell lung cancer: Fulvestrant/Faslodex, a Selective estrogen receptor down-regulator, suppresses the expression of ITGB3 via up regulation of its target gene, 11/May/2014, 6.08 am
May 11, 2014
Tumor suppression: Resistin, a pro-inflammatory cytokine, suppresses the expression of Polypyrimidine Tract Binding Protein-1 (PTB1) via up regulation of its target gene, 11/May/2014, 8.20 am
May 11, 2014
Show all

A study from Watson School of Biological Sciences shows that SRSF1 is a critical transcriptional target of c-MYC.  This study was published in the Feb 20, 2012 Cell  Rep by Prof. Dr Krainer AR & Das, Watson School of Biological Sciences, USA.

On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: Molecular cancer therapy: Tumor suppressor p53 suppresses the expression of SRSF1 via up regulation of its target gene. This data suggest that p53, by suppressing the expression of SRSF1, it will inhibit the expression of a number of oncogenic mRNAs in cancer cells.

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan,  Molecular cancer therapy: Tumor suppressor p53 suppresses the expression of SRSF1 via up regulatin of its target gene,  11/May/2014, 8.09 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

*Research cooperation

Comments are closed.